Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
about
Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthroughAdditional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthroughLansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer PhenotypeAdditional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough: a Cochrane systematic review.Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypesCYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori.Pharmacogenomics of proton pump inhibitors.CYP2C19 polymorphism and proton pump inhibitors.Efficacy of esomeprazole in treating acid-related diseases in Japanese populationsRole of cytochrome P450 genotype in the steps toward personalized drug therapy.Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A ReviewIndividualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial.Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist.Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.Severity of gastric mucosal atrophy affects the healing speed of post-endoscopic submucosal dissection ulcers.
P2860
Q24240662-B910247F-1D9C-4B67-8C6A-0A76676336BAQ24246606-C11589B8-643C-499F-8103-3D124E557856Q30300235-E6836E46-DDE0-46BC-BE5C-B84D9F4E66DEQ33248384-FAD08536-F237-4091-8D73-97045E8EC155Q34174915-BB36D4E1-32F9-4284-88F9-2BD3492294B0Q34583603-3AD89148-23A2-4364-B97A-02B2987FA589Q35082607-02F20AF0-56F2-477F-95AB-55340A02540CQ35689146-F5875C22-F3F9-4B61-87FC-4BE5815637A3Q35831792-2312AC9F-F942-4531-8DE2-DD654F70BE88Q35987201-637CDF1B-924E-4FFC-B352-E05DC5247F6DQ36441521-52744F1F-B96E-4070-A047-2D86A80E6416Q36979297-AB253B5E-D5FA-476A-B863-45C4D3E5A8D1Q38031223-EE49DF7C-AB0F-4F35-8CA8-CF31ADEFE720Q38032920-EF3D0692-F01E-4DF8-A664-0AAE99EAB9EEQ38219028-EBE7AF4D-3971-4088-86C4-C347CCAD1B62Q38861693-17FDD251-63E4-4C59-B6D6-0BF2F85927AFQ39014375-E79A9E97-7D2C-4571-A3D9-D75F5360F348Q39420822-1AEEEAF3-77F3-4473-B213-C04C2CC59528Q39496600-70AA14C3-F846-4530-B92D-1B82A8884386Q39496607-83B17A17-FA48-4B54-9F32-466F23416701Q39496624-895A5CDA-5CA2-4118-A073-C690D1B82BF2Q39543475-4184CE18-9C05-46B9-9908-FB2D35939CC7Q39617600-90E33CDF-2652-45C0-8695-4D9866FFFCE6Q44678734-2E72DF5E-AFC2-4EB0-A667-8617F09C7BD4Q45264304-BECE2C07-67CA-4F78-AEEE-E2E50F936CEBQ46552861-C516C36F-8957-4595-9A44-9FA9AB093247Q55248755-E459FE82-A192-4ECB-BA40-6D81A44DE757
P2860
Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Comparison of lansoprazole and ...... erent CYP2C19 genotype groups.
@en
Comparison of lansoprazole and ...... erent CYP2C19 genotype groups.
@nl
type
label
Comparison of lansoprazole and ...... erent CYP2C19 genotype groups.
@en
Comparison of lansoprazole and ...... erent CYP2C19 genotype groups.
@nl
prefLabel
Comparison of lansoprazole and ...... erent CYP2C19 genotype groups.
@en
Comparison of lansoprazole and ...... erent CYP2C19 genotype groups.
@nl
P2093
P2860
P1476
Comparison of lansoprazole and ...... erent CYP2C19 genotype groups.
@en
P2093
M Kajimura
T Ishizaki
P2860
P304
P356
10.1046/J.1365-2036.2002.01229.X
P407
P577
2002-04-01T00:00:00Z